Related Experiment Video
Updated: Aug 8, 2025
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
LncRNA and its role in gastric cancer immunotherapy
Qiang Zhang1, Chuanchi Wang2,3, Yan Yang3
1Department of Digestive endoscopy, Jiangsu Province Hospital of Traditional Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Abstract:
Gastric cancer (GC) is a potential dominant disease in tumor immunotherapy checkpoint inhibitors, and adoptive cell therapy have brought great hope to GC patients. However, only some patients with GC can benefit from immunotherapy, and some patients develop drug resistance. More and more studies have shown that long non-coding RNAs (lncRNAs) may be important in GC immunotherapy's prognosis and drug resistance. Here, we summarize the differential expression of lncRNAs in GC and their impact on the curative effect of GC immunotherapy, discuss potential mechanisms of activity in GC immunotherapy resistance regulated by lncRNAs. This paper reviews the differential expression of lncRNA in GC and its effect on immunotherapy efficacy in GC. In terms of genomic stability, inhibitory immune checkpoint molecular expression, the cross-talk between lncRNA and immune-related characteristics of GC was summarized, including tumor mutation burden (TMB), microsatellite instability (MSI), and Programmed death 1 (PD-1). At the same time, this paper reviewed the mechanism of tumor-induced antigen presentation and upregulation of immunosuppressive factors, as well as the association between Fas system and lncRNA, immune microenvironment (TIME) and lncRNA, and summarized the functional role of lncRNA in tumor immune evasion and immunotherapy resistance.
Insights
Long non-coding RNAs (lncRNAs) play a crucial role in gastric cancer (GC) immunotherapy. Understanding lncRNA expression and function is key to overcoming resistance and improving treatment outcomes for GC patients.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Gastric cancer (GC) immunotherapy offers hope but faces challenges with limited patient benefit and acquired drug resistance.
- Long non-coding RNAs (lncRNAs) are increasingly recognized for their potential involvement in GC immunotherapy prognosis and resistance.
Purpose of the Study:
- To summarize the differential expression of lncRNAs in GC.
- To elucidate the impact of lncRNAs on GC immunotherapy efficacy and resistance.
- To review the mechanisms by which lncRNAs regulate GC immune evasion and treatment response.
Main Methods:
- Literature review and synthesis of existing research on lncRNAs in GC immunotherapy.
- Analysis of lncRNA interactions with genomic stability, immune checkpoints (e.g., PD-1), and immune characteristics (TMB, MSI).
- Examination of lncRNA roles in antigen presentation, immunosuppression, Fas system, and the tumor immune microenvironment (TIME).
Main Results:
- lncRNAs are differentially expressed in GC and influence immunotherapy outcomes.
- lncRNAs modulate genomic stability, immune checkpoint expression, and tumor mutational characteristics.
- lncRNAs are implicated in tumor immune evasion through antigen presentation, immunosuppressive factors, and TIME modulation.
Conclusions:
- lncRNAs are critical regulators of gastric cancer's response to immunotherapy.
- Targeting lncRNAs presents a potential strategy to enhance immunotherapy efficacy and overcome resistance in GC.
- Further research into lncRNA mechanisms is essential for advancing GC immunotherapy.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...